New CAR-Treg cell collab for Quell Therapeutics

8 April 2020

2019_vial_production_biotech_manufacturing_big

London-based cell therapy specialist Quell Therapeutics has kicked off a new collaboration with the Hannover Medical School, Germany, aimed at the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.

Quell Therapeutics was set up in 2019 by life sciences investment trust Syncona (LSE: SYNC), with a series A investment of £34 million ($42 million).

The firm was founded in partnership with six experts in the fields of Treg, cell engineering, solid organ transplantation and autoimmune diseases from King’s College London, University College London (UCL), and Hannover Medical School.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK